Retatrutide Side Effects: What to Expect During Treatment

Key takeaways

• Gastrointestinal side effects (nausea, diarrhea, vomiting) are the most common and usually occur during dose escalation
• Starting at a lower dose (2 mg instead of 4 mg) reduced GI symptom frequency in clinical trials
• A new safety signal called dysesthesia (abnormal touch sensations) appeared in phase 3 data at higher doses
• Most side effects are mild to moderate and improve once a stable maintenance dose is reached
• Discontinuation rates in phase 3 ranged from 12-18%, with some patients stopping due to excessive weight loss

The side effect profile of retatrutide looks a lot like what you’d expect from a GLP-1 medication, with one twist. Because retatrutide activates three receptors instead of one or two, there are both familiar patterns and some new signals that didn’t show up with semaglutide or tirzepatide.

Two major clinical trials provide the safety data: a phase 2 trial of 338 adults published in the New England Journal of Medicine (Jastreboff et al., 2023) and the phase 3 TRIUMPH-4 trial reported by Eli Lilly in December 2025 [1, 2]. Here’s what they found.

Gastrointestinal side effects

GI symptoms are the most reported adverse events across both trials. They’re also the most predictable. If you’ve read about peptide side effects from GLP-1 medications, this will sound familiar.

Nausea

Nausea was the single most common side effect. In the phase 2 trial, rates ranged from 14% at the lowest dose (1 mg) to roughly 60% at the 12 mg dose, compared to about 10% with placebo. In TRIUMPH-4, the nausea rate was 43% across the higher-dose groups [1, 2].

The important detail: nausea was front-loaded. It occurred primarily during the dose escalation period (the first 8-12 weeks when doses are being increased every 4 weeks) and improved once participants reached a stable maintenance dose [1].

Diarrhea

Diarrhea rates ranged from 9% to 20% in phase 2, depending on the dose. In TRIUMPH-4, the rate was 33% at the 12 mg dose. Most cases were mild to moderate and transient [1, 2].

Vomiting

Vomiting occurred in 3-26% of participants across dose groups in phase 2. The TRIUMPH-4 rate was 21%. Like nausea, vomiting clustered during dose escalation rather than at maintenance doses [1, 2].

Constipation

Constipation was reported across dose groups but less frequently than nausea, diarrhea, and vomiting. GLP-1 agonists slow gastric emptying, which can reduce bowel movement frequency. Adequate hydration and fiber intake can help manage this [1].

Why GI effects happen

Retatrutide activates GLP-1 receptors, which slow gastric emptying and alter gut motility. Your stomach takes longer to empty, food sits there longer, and the signaling changes in your GI tract can trigger nausea. GIP and glucagon receptor activation may contribute additional GI effects, though GLP-1 is the primary driver [3].

The good news: these symptoms typically decrease over time. The body adjusts to the receptor activation, and the dose escalation protocol is specifically designed to minimize GI impact. The phase 2 trial showed that starting at 2 mg (instead of jumping straight to 4 mg) meaningfully reduced GI side effects during titration [1].

Heart rate changes

Retatrutide caused dose-dependent increases in heart rate in the phase 2 trial. The increases peaked at about 24 weeks and then declined [1].

This is consistent with other GLP-1 receptor agonists. Semaglutide and tirzepatide both produce small heart rate increases, typically 2-4 beats per minute. The mechanism isn’t entirely clear, but it may relate to sympathetic nervous system activation or direct cardiac GLP-1 receptor effects [3].

The heart rate changes did not appear to cause clinical events in the trial, but they explain why cardiovascular monitoring is standard during GLP-1 treatment.

Dysesthesia (new phase 3 signal)

This is the one side effect that wasn’t seen in phase 2 and caught attention when the TRIUMPH-4 results came out in December 2025.

Dysesthesia is an abnormal sensation of touch where normal stimuli feel unusual, uncomfortable, or even painful. Think of it as your skin or nerves misinterpreting normal sensations. It can manifest as tingling, burning, prickling, or a feeling that something light is pressing too hard [2].

In TRIUMPH-4:

• 0.7% on placebo reported dysesthesia
• 8.8% on the 9 mg dose
• 20.9% on the 12 mg dose

This is a significant dose-response relationship. The events did not appear to cause treatment discontinuation, and Eli Lilly noted they were not associated with other neurological findings [2]. But this is a new signal. It wasn’t reported in the phase 2 trial of 338 participants, which may mean it either requires longer treatment duration to emerge, or it was too rare to detect in a smaller study.

The remaining TRIUMPH phase 3 trials will provide more data on dysesthesia prevalence, timing, and whether it resolves after stopping treatment.

Decreased appetite

Reduced appetite is both an intended effect and a reported side effect. In clinical trials, it was listed as an adverse event because some participants experienced appetite suppression that went beyond what they considered comfortable. This is part of how the drug produces weight loss, but for some patients, the degree of appetite reduction can feel excessive, particularly at higher doses [1].

Injection site reactions

Mild injection site reactions (redness, itching, or minor swelling) occurred in some participants. These are typical of subcutaneous peptide injections and generally resolve within hours to days. Rotating injection sites between the abdomen, thigh, and upper arm helps minimize these reactions [1].

For general guidance on subcutaneous injections, see our peptide injection guide.

Discontinuation rates

In the phase 3 TRIUMPH-4 trial [2]:

• Placebo: 4% discontinued
• 9 mg dose: 12.2% discontinued
• 12 mg dose: 18.2% discontinued

Some discontinuations at the 12 mg dose were attributed to “perceived excessive weight loss,” particularly in participants with lower starting BMI. Patients with higher BMI had lower discontinuation rates [2].

For comparison, discontinuation rates across published semaglutide and tirzepatide trials typically range from 5-15%. Retatrutide’s rates at the highest dose are on the higher end, but the degree of weight loss is also substantially greater.

Managing side effects

Based on the clinical trial protocols and general GLP-1 treatment experience [1, 4]:

For nausea: Eat smaller, more frequent meals. Avoid greasy or heavy foods, especially during the first few weeks of each dose increase. Some patients find ginger tea helpful. If nausea persists beyond 2-3 weeks at a given dose, discuss holding the current dose longer before escalating.

For diarrhea: Stay well hydrated with water and electrolytes. Avoid high-fat meals that may worsen GI motility issues. Most diarrhea resolves as the body adjusts.

For constipation: Increase water intake and dietary fiber. Regular physical activity also helps. If constipation is persistent, a mild osmotic laxative may be appropriate (discuss with your provider).

For injection site reactions: Rotate injection sites. Allow the alcohol swab to fully dry before injecting. If redness or swelling worsens rather than improving, contact your provider.

General approach: The retatrutide dosing protocol uses 4-week intervals between dose escalations for a reason. Extending these intervals (holding at a given dose for 6-8 weeks instead of 4) may reduce GI side effects for patients who are particularly sensitive.

Who should not take retatrutide

While formal contraindications haven’t been established through FDA approval, clinical trial exclusion criteria provide guidance. Retatrutide trials typically excluded participants with [1]:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• History of pancreatitis
• Severe gastrointestinal disease
• Significant cardiovascular events within the past 6 months
• eGFR below 30 mL/min/1.73 m² (severe kidney impairment)
• Current pregnancy or breastfeeding

Anyone considering retatrutide should have a thorough medical evaluation first. The drug’s triple-receptor mechanism means it affects more metabolic pathways than single- or dual-agonist medications, and baseline lab work (kidney function, liver enzymes, thyroid function, lipid panel) is standard before starting treatment.

How retatrutide side effects compare to other GLP-1 medications

Side effect	Retatrutide (12 mg)	Tirzepatide (15 mg)	Semaglutide (2.4 mg)
Nausea	43-60%	20-30%	44%
Diarrhea	20-33%	17-23%	30%
Vomiting	21-26%	9-13%	24%
Constipation	Reported	11-12%	24%
Dysesthesia	8.8-20.9%	Not reported	Not reported

The GI side effect rates are broadly similar across these medications, though the dysesthesia signal is unique to retatrutide so far. The higher nausea rates at the 12 mg dose in phase 2 (up to 60%) reflect the earlier trial design where some patients started at higher initial doses [1, 2, 5].

Frequently asked questions

Do retatrutide side effects go away?▼

Most GI side effects improve significantly after the dose escalation phase. In the phase 2 trial, gastrointestinal events were primarily reported during the first 8-12 weeks of dose increases and decreased once participants reached their maintenance dose [1].

Is retatrutide harder to tolerate than semaglutide?▼

Not necessarily. The GI side effect rates are comparable. The key difference is the dysesthesia signal seen in phase 3, which hasn’t been reported with semaglutide or tirzepatide. For GI tolerance, the gradual dose escalation starting at 2 mg helps most patients adjust [1, 2].

What is dysesthesia and should I be worried?▼

Dysesthesia is an abnormal touch sensation. It occurred in up to 20.9% of participants on the 12 mg dose in TRIUMPH-4. While notable, the events did not cause treatment discontinuation and were not associated with other neurological findings. More data from ongoing trials will clarify its significance [2].

Can I take retatrutide if I have diabetes?▼

Retatrutide has been studied in adults with type 2 diabetes and showed improvements in both blood sugar control and body weight. However, the drug is not FDA-approved for any indication. If you have diabetes, any use of retatrutide should be closely monitored by your healthcare provider, particularly for hypoglycemia risk when combined with insulin or sulfonylureas [6].

What should I do if side effects are severe?▼

Contact your healthcare provider. Options include extending the time between dose escalations (holding at a current dose for 6-8 weeks), reducing the dose temporarily, or discontinuing treatment if adverse events are not tolerable. Never adjust dosing on your own without medical guidance.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release. December 11, 2025.
3. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013
4. The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese adolescents without diabetes mellitus: a systematic review and meta-analysis. Cureus. 2024;16(8):e66643. PMID:39238716
5. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
6. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.